ALK B ALK-ABELLO A/S

Release date of nine-month interim report (Q3) 2023 for ALK and audio cast

Release date of nine-month interim report (Q3) 2023 for ALK and audio cast

On Wednesday, 15 November 2023 ALK (ALKB:DC / OMX: ALK B / AKBLF) releases its nine-month interim report (Q3) 2023.

ALK will host a meeting for analysts and institutional investors that day at 1.30pm (CET) at which Management will review the financial results, the outlook and answer questions.

The meeting will be audio cast live on our website , where the related presentation will be available shortly before the meeting begins.

To register for the conference call, please use this link and follow the instructions. You will receive an email from with dial-in details, including a passcode and a pin code. Please make sure to whitelist and/or check your spam filter. We advise you to register on the day before the call at the latest.

ALK-Abelló A/S

For further information please contact:

Investor Relations: Per Plotnikof, tel. , mobile

Media: Maiken Riise Andersen, tel.

About ALK

ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,700 people worldwide and is listed on Nasdaq Copenhagen. Find more information at

Attachment



EN
09/11/2023

Underlying

ALK BALK-ABELLO A/S

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ALK-ABELLO A/S

 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

ALK og GenSci indgår partnerskab om at udvide AIT-markedet i Kina

ALK og GenSci indgår partnerskab om at udvide AIT-markedet i Kina Intern viden GenSci tildeles eksklusive rettigheder til ALK’s AIT-produkter mod husstøvmideallergi i Kina.ALK vil være berettiget til upfront- og milepælsbetalinger på op til DKK 1,3 milliarder ud over indtægter fra levering af produkter til GenSci.Partnerskabet har også til formål at fremskynde introduktionen af en bredere portefølje i Kina.Partnerskabet forventes at understøtte indtjeningsmarginen på mellemlangt sigt, men forventes ikke at have væsentlig indvirkning på ALK’s omsætning og indtjening (EBIT) i 2025. ALK (ALK...

September 17, 2025 1 EN
 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

ALK and GenSci partner to expand the AIT market in China

ALK and GenSci partner to expand the AIT market in China Inside Information GenSci is granted exclusive rights to ALK’s house dust mite AIT products in China. ALK will be eligible for upfront and milestone payments of up to DKK 1.3 billion in addition to income from supplying GenSci with products.Partnership also aims to accelerate the introduction of a broader portfolio in China.Partnership is projected to become accretive to earnings margin in the medium term but is not expected to materially impact ALK’s revenue and earnings (EBIT) in 2025. ALK (ALKB:DC / OMX: ALK B) today announced a...

September 17, 2025 1 EN
 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

Real-world evidence supports clinical effectiveness of the neffy® nasa...

Real-world evidence supports clinical effectiveness of the neffy® nasal adrenaline spray ALK (ALKB:DC / OMX: ALK B) today announced that real-world evidence evaluating the clinical performance of the nasal adrenaline spray neffy® in US patients experiencing anaphylaxis symptoms during oral food challenge and allergen immunotherapy has been accepted for scientific publication. The findings represent the first large-scale analysis of treatment outcomes with neffy® during routine clinical practice and were accepted for publishing as a correspondence in the Annals of Allergy, Asthma and Immunol...

September 8, 2025 1 EN
 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

ALK udvider den øverste ledelse med regionale nøglemarkeder

ALK udvider den øverste ledelse med regionale nøglemarkeder ALK (ALKB:DC / OMX: ALK B) har i dag annonceret en beslutning om, at geografiske nøglemarkeder skal indgå i selskabets øverste ledelse, det såkaldte Executive Leadership Team (ELT), for at styrke eksekveringen af ALK’s strategi, Allergy+. Fra 1. oktober 2025 vil ALK’s to primære geografiske markeder, Europa og Nordamerika, være direkte repræsenteret i ELT. Flora Beiche-Scholz – som på nuværende tidspunkt besidder stillingen som Senior Vice President for Europa – vil indtræde i ELT i en nyoprettet stilling som Executive Vice Presid...

September 4, 2025 1 EN
 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

ALK expands the Executive Leadership Team to include key commercial re...

ALK expands the Executive Leadership Team to include key commercial regions ALK (ALKB:DC / OMX: ALK B) today announced the decision to elevate its key commercial regions into the Executive Leadership Team (ELT) to further strengthen the execution of ALK’s strategy, Allergy+. Effective as of 1 October 2025, ALK’s two key commercial regions, Europe and North America, will be directly represented in the ELT. Dr. Flora Beiche-Scholz – who currently holds the position as Senior Vice President for region Europe – will join the ELT in a new position as Executive Vice President (EVP) and head of...

September 4, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch